The PD-1:PD-L1 axis in Inflammatory Arthritis
Abstract The activation of antigen specific T cells during an immune response is a tightly regulated process at the level of both costimulatory and coinhibitory receptors. One such coinhibitory receptor or checkpoint inhibitor which has received much attention in the field of oncology is the program...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2021-01-01
|
| Series: | BMC Rheumatology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s41927-020-00171-2 |
| _version_ | 1818960356703207424 |
|---|---|
| author | Mary Canavan Achilleas Floudas Douglas J. Veale Ursula Fearon |
| author_facet | Mary Canavan Achilleas Floudas Douglas J. Veale Ursula Fearon |
| author_sort | Mary Canavan |
| collection | DOAJ |
| description | Abstract The activation of antigen specific T cells during an immune response is a tightly regulated process at the level of both costimulatory and coinhibitory receptors. One such coinhibitory receptor or checkpoint inhibitor which has received much attention in the field of oncology is the programmed cell death protein 1 (PD-1). Blockade of PD-1 or its ligand PD-L1 has proven successful in the treatment of a wide variety of cancers, therefore highlighting an important role for this pathway in anti-tumour immune responses. However, a caveat of PD-1 therapy and boosting anti-tumour immune responses is the development of self-reactive T cells which can lead to the induction of various autoimmune or inflammatory diseases, referred to as immune- related adverse events (irAEs). The emergence of rheumatological irAEs such as Inflammatory Arthritis (IA) in recent years has highlighted the importance of PD-1 in maintaining self-tolerance. Furthermore, the emergence of rheumatology related irAEs raises an important question as to how defects in this pathway can contribute to spontaneous rheumatological disease. In this review, we describe the biological distribution, function and regulation of the PD-1 pathway, its potential role in IA and irAE related IA. |
| first_indexed | 2024-12-20T11:56:14Z |
| format | Article |
| id | doaj.art-758799aa613d4acd8d20ec134d4da8a0 |
| institution | Directory Open Access Journal |
| issn | 2520-1026 |
| language | English |
| last_indexed | 2024-12-20T11:56:14Z |
| publishDate | 2021-01-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Rheumatology |
| spelling | doaj.art-758799aa613d4acd8d20ec134d4da8a02022-12-21T19:41:38ZengBMCBMC Rheumatology2520-10262021-01-015111010.1186/s41927-020-00171-2The PD-1:PD-L1 axis in Inflammatory ArthritisMary Canavan0Achilleas Floudas1Douglas J. Veale2Ursula Fearon3Department of Molecular Rheumatology, Trinity Biomedical Sciences Institute, Trinity College DublinDepartment of Molecular Rheumatology, Trinity Biomedical Sciences Institute, Trinity College DublinEULAR Centre of Excellence, Centre for Arthritis & Rheumatic Diseases, St. Vincent’s University Hospital, University College DublinDepartment of Molecular Rheumatology, Trinity Biomedical Sciences Institute, Trinity College DublinAbstract The activation of antigen specific T cells during an immune response is a tightly regulated process at the level of both costimulatory and coinhibitory receptors. One such coinhibitory receptor or checkpoint inhibitor which has received much attention in the field of oncology is the programmed cell death protein 1 (PD-1). Blockade of PD-1 or its ligand PD-L1 has proven successful in the treatment of a wide variety of cancers, therefore highlighting an important role for this pathway in anti-tumour immune responses. However, a caveat of PD-1 therapy and boosting anti-tumour immune responses is the development of self-reactive T cells which can lead to the induction of various autoimmune or inflammatory diseases, referred to as immune- related adverse events (irAEs). The emergence of rheumatological irAEs such as Inflammatory Arthritis (IA) in recent years has highlighted the importance of PD-1 in maintaining self-tolerance. Furthermore, the emergence of rheumatology related irAEs raises an important question as to how defects in this pathway can contribute to spontaneous rheumatological disease. In this review, we describe the biological distribution, function and regulation of the PD-1 pathway, its potential role in IA and irAE related IA.https://doi.org/10.1186/s41927-020-00171-2Checkpoint inhibitorsPD-1Rheumatoid arthritisPsoriatic arthritisAdverse events |
| spellingShingle | Mary Canavan Achilleas Floudas Douglas J. Veale Ursula Fearon The PD-1:PD-L1 axis in Inflammatory Arthritis BMC Rheumatology Checkpoint inhibitors PD-1 Rheumatoid arthritis Psoriatic arthritis Adverse events |
| title | The PD-1:PD-L1 axis in Inflammatory Arthritis |
| title_full | The PD-1:PD-L1 axis in Inflammatory Arthritis |
| title_fullStr | The PD-1:PD-L1 axis in Inflammatory Arthritis |
| title_full_unstemmed | The PD-1:PD-L1 axis in Inflammatory Arthritis |
| title_short | The PD-1:PD-L1 axis in Inflammatory Arthritis |
| title_sort | pd 1 pd l1 axis in inflammatory arthritis |
| topic | Checkpoint inhibitors PD-1 Rheumatoid arthritis Psoriatic arthritis Adverse events |
| url | https://doi.org/10.1186/s41927-020-00171-2 |
| work_keys_str_mv | AT marycanavan thepd1pdl1axisininflammatoryarthritis AT achilleasfloudas thepd1pdl1axisininflammatoryarthritis AT douglasjveale thepd1pdl1axisininflammatoryarthritis AT ursulafearon thepd1pdl1axisininflammatoryarthritis AT marycanavan pd1pdl1axisininflammatoryarthritis AT achilleasfloudas pd1pdl1axisininflammatoryarthritis AT douglasjveale pd1pdl1axisininflammatoryarthritis AT ursulafearon pd1pdl1axisininflammatoryarthritis |